АлергоМакс, the tab., п / oh, on 5 mg No. 10

General characteristics. Structure:

Active ingredient: desloratadine; 1 tablet contains a dezloratadin of 5 mg; Excipients: calcium hydrophosphate; magnesium stearate cellulose microcrystallic (type 101 and type 102); lactose, monohydrate of a gipromelloz; starch corn; titanium dioxide (Е 171); indigo carmine (Е 132).

Pharmacological properties:

Dezloratadin - the selection blocker peripheral H1 receptors, does not render sedation. Dezloratadin is primary active metabolite of a loratadin. In researches of a dezloratadin and loratadin of qualitative or quantitative distinctions of toxicity of two drugs in the compared doses (taking into account concentration of a dezloratadin) it is not revealed.

After oral administration drug selectively blocks peripheral N _{1 -} histamine receptors and does not get through a blood-brain barrier.

Except antihistaminic activity, drug   has antiallergic and antiinflammatory effect. It is established what д езлоратадин suppresses the cascade of various reactions which are the cornerstone of development of an allergic inflammation namely:

release of antiinflammatory cytokines, including IL-4, IL-6, IL-8, IL-13;

release of antiinflammatory chemokines, such as RANTES;

products of superoxidic anion the activated polymorphonuclear neutrophils;

adhesion and chemotaxis of eosinophils;

expression of molecules of adhesion, such, as R-selectin;

IgE-dependent allocation of a histamine, D2 prostaglandin and C4 leukotriene;

acute allergic bronchospasm in researches on animals.

The N е gets through a blood-brain barrier.

Dezloratadin begins to be defined in plasma within 30 min. after reception. The maximum concentration of a dezloratadin in plasma is reached on average in 3 hours, the elimination half-life makes, on average, 27 hours. Extent of cumulation of a dezloratadin corresponds its elimination half-life (about 27 hours) and frequency rates of use (once a day). Bioavailability of a dezloratadin was proportional to a dose in the range from 5 to 20 mg.

Dezloratadin moderately (83 - 87%) contacts proteins of plasma.

The conducted researches showed what дезлоратадин does not suppress CYP3A4 or CYP2D6 and is not either substrate, or R-glycoprotein inhibitor.

 

Indications to use:

For bystry elimination of allergic symptoms: 

- A pollinosis and allergic rhinitis (sneezing, allocations from a nose, an itch, hypostasis and a congestion of a nose, dacryagogue and reddening of eyes, an itch in the field of the sky and cough);

- elimination of the symptoms connected with  a small tortoiseshell oh such as an itch, and rashes.

Route of administration and doses:

Drug is intended for oral administration. Adults and children are more senior than 12 years accept on one tablet (5 mg) once a day, irrespective of meal. It is necessary to swallow of a tablet entirely, washing down with water. It is regularly desirable to accept drug, at the same time days. Duration of treatment is defined by weight and the course of a disease.

Therapy of intermittent allergic rhinitis (existence of symptoms less than 4 days a week or less than 4 weeks) needs to be carried out taking into account data of the anamnesis: to stop after disappearance of symptoms and to recover after their repeated emergence.

At persistent allergic rhinitis (existence of symptoms more than 4 days a week or more than 4 weeks) it is necessary to continue treatment during the entire period of contact with allergen.

Features of use:

Duty. Surely report to the doctor about your previous reaction to use of drugs of this group.
 
Use during pregnancy or feeding by a breast. Safety of use of drug for pregnant women is not established therefore it is not recommended to appoint it during pregnancy. Dezloratadin gets into breast milk therefore the women nursing should not appoint drug.
 
Ability to influence speed of response at control of motor transport or other mechanisms. Influence on driving or work with difficult technical devices was not noted.
 
Children. Drug is contraindicated to children up to 12 years.

Side effects:

At drug use increased fatigue (1,2%), dryness in a mouth (0,8%), a headache (0,6%) were the frequent undesirable phenomena.

It was very seldom reported about hypersensitivity reaction (including an anaphylaxis and rash), tachycardia, heartbeat, a psychomotor hyperactivity, spasms, increase in activity of liver enzymes, increase in level of bilirubin, development of hepatitis.

In case of any unusual reactions surely consult to the doctor of rather further use of drug.

Interaction with other medicines:

Clinically significant changes in plasma concentration of a dezloratadin at numerous combined use with ketokonazoly, erythromycin, azithromycin, fluoxetine, Cimetidinum it was revealed not. Because the enzyme which is responsible for metabolism of a dezloratadin unspecified interaction with other medicines completely cannot be excluded.

Dezloratadin did not strengthen such effects of alcohol as disturbance of psychomotor function and drowsiness.

Contraindications:

Hypersensitivity to active agent or to any of an inactive component of drug.

Age up to 12 years.

Pregnancy and period of feeding by a breast.

Overdose:

In case of overdose the standard actions directed to removal not absorbed active agent are shown. Symptomatic treatment.

Is not removed at a hemodialysis, the possibility of its removal at peritoneal dialysis is not established.

Storage conditions:

To store in original packaging at a temperature not above 25 °C. To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Tabletka, coated, on 5 mg No. 10, No. 10х2 in the blister in a box.